Literature DB >> 29241744

Fragility of Results in Ophthalmology Randomized Controlled Trials: A Systematic Review.

Carl Shen1, Isabel Shamsudeen2, Forough Farrokhyar3, Kourosh Sabri4.   

Abstract

PURPOSE: Evidence-based medicine is guided by our interpretation of randomized controlled trials (RCTs) that address important clinical questions. Evaluation of the robustness of statistically significant outcomes adds a crucial element to the global assessment of trial findings. The purpose of this systematic review was to determine the robustness of ophthalmology RCTs through application of the Fragility Index (FI), a novel metric of the robustness of statistically significant outcomes.
DESIGN: Systematic review.
METHODS: A literature search (MEDLINE) was performed for all RCTs published in top ophthalmology journals and ophthalmology-related RCTs published in high-impact journals in the past 10 years. Two reviewers independently screened 1811 identified articles for inclusion if they (1) were a human ophthalmology-related trial, (2) had a 1:1 prospective study design, and (3) reported a statistically significant dichotomous outcome in the abstract. All relevant data, including outcome, P value, number of patients in each group, number of events in each group, number of patients lost to follow-up, and trial characteristics, were extracted. The FI of each RCT was calculated and multivariate regression applied to determine predictive factors.
RESULTS: The 156 trials had a median sample size of 91.5 (range, 13-2593) patients/eyes, and a median of 28 (range, 4-2217) events. The median FI of the included trials was 2 (range, 0-48), meaning that if 2 non-events were switched to events in the treatment group, the result would lose its statistical significance. A quarter of all trials had an FI of 1 or less, and 75% of trials had an FI of 6 or less. The FI was less than the number of missing data points in 52.6% of trials. Predictive factors for FI by multivariate regression included smaller P value (P < 0.001), larger sample size (P = 0.001), larger number of events (P = 0.011), and journal impact factor (P = 0.029).
CONCLUSIONS: In ophthalmology trials, statistically significant dichotomous results are often fragile, meaning that a difference of only a couple of events can change the statistical significance. An application of the FI in RCTs may aid in the interpretation of results and assessment of quality of evidence.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29241744     DOI: 10.1016/j.ophtha.2017.11.015

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

1.  Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis.

Authors:  X Huang; B Chen; L Thabane; J D Adachi; G Li
Journal:  Osteoporos Int       Date:  2021-02-17       Impact factor: 4.507

2.  Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package.

Authors:  Lifeng Lin; Haitao Chu
Journal:  PLoS One       Date:  2022-06-01       Impact factor: 3.752

3.  The Fragility Index of Randomized Controlled Trials for Preterm Neonates.

Authors:  Huiyi Li; Zhenyu Liang; Qiong Meng; Xin Huang
Journal:  Front Pediatr       Date:  2022-05-09       Impact factor: 3.569

4.  Randomized controlled trials in ophthalmology: a bibliometric study.

Authors:  Saif Aldeen AlRyalat; Areen Abukahel; Khaled Ali Elubous
Journal:  F1000Res       Date:  2019-10-04

5.  On clinical trial fragility due to patients lost to follow up.

Authors:  Benjamin R Baer; Stephen E Fremes; Mario Gaudino; Mary Charlson; Martin T Wells
Journal:  BMC Med Res Methodol       Date:  2021-11-20       Impact factor: 4.615

6.  The Fragility of Significance in the Hip Arthroscopy Literature: A Systematic Review.

Authors:  Robert L Parisien; David P Trofa; Michaela O'Connor; Brock Knapp; Emily J Curry; Paul Tornetta; T Sean Lynch; Xinning Li
Journal:  JB JS Open Access       Date:  2021-10-21

7.  The Fragility Index for Assessing the Robustness of the Statistically Significant Results of Experimental Clinical Studies.

Authors:  Adrienne K Ho
Journal:  J Gen Intern Med       Date:  2021-08-06       Impact factor: 5.128

8.  How Robust are the Evidences that Formulate Surviving Sepsis Guidelines? An Analysis of Fragility and Reverse Fragility of Randomized Controlled Trials that were Referred in these Guidelines.

Authors:  Nang S Choupoo; Saurabh K Das; Priyam Saikia; Samarjit Dey; Sumit Ray
Journal:  Indian J Crit Care Med       Date:  2021-07

9.  Treatment of Symptomatic Convergence Insufficiency in Children Enrolled in the Convergence Insufficiency Treatment Trial-Attention & Reading Trial: A Randomized Clinical Trial.

Authors: 
Journal:  Optom Vis Sci       Date:  2019-11       Impact factor: 1.973

10.  Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Authors:  Brooke E Wilson; Alexandra Desnoyers; Michelle B Nadler; Ariadna Tibau; Eitan Amir
Journal:  Cancer Med       Date:  2021-07-28       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.